Larkspur Biosciences is developing the next generation of precision immunotherapies to combat cancer. Despite advances in cancer treatments, many cancer patients still do not respond to existing options. Using LarkX, their proprietary machine learning-enabled gene signature platform, Larkspur’s approach is to target cancer-intrinsic factors that tumors use to escape immune detection. The bioinformatics approach focuses treatment on likely responders so that more targeted trials can be conducted. Larkspur’s lead program is a novel approach to improve antigen-presenting function through lipid remodeling, with other programs in development for colorectal cancer.

Larkspur Biosciences

Founded: 2023
Location: Watertown, MA
Employee range: 11 - 50
Clinical stage: RD
Therapy area: cancer
Drug types: ONC
Funding: $35.5M Seed/A May 2023
Investors: Polaris Innovation Fund, 3E Bioventures Capital, Takeda Ventures, Creacion Ventures, Med-Fine Capital, Cornell University

Business:

About:

Jobs:

News: